• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Transbound Emerg Dis . The Functional DPP4 Receptor Is an Indispensable Factor Mediating the Immune Performance of Mucosal Vaccines for Middle East

tetano

Editor, Senior Moderator
Transbound Emerg Dis


. 2025 Jun 10:2025:2303502.
doi: 10.1155/tbed/2303502. eCollection 2025. The Functional DPP4 Receptor Is an Indispensable Factor Mediating the Immune Performance of Mucosal Vaccines for Middle East Respiratory Syndrome

Zhenshan Wang[SUP] 1 2 [/SUP], Xiaojun Hu[SUP] 1 2 [/SUP], Shen Wang[SUP] 2 [/SUP], Hongyu Sun[SUP] 1 2 [/SUP], Yongkun Zhao[SUP] 2 [/SUP], Na Feng[SUP] 2 [/SUP], Tiecheng Wang[SUP] 2 [/SUP], Guixue Hu[SUP] 1 [/SUP], Jianzhong Wang[SUP] 1 [/SUP], Xianzhu Xia[SUP] 1 2 3 [/SUP], Feihu Yan[SUP] 2 [/SUP]



Affiliations
Abstract

Mucosal vaccines are powerful tools for combatting emerging infectious diseases, particularly mucosal-associated pathogens. However, one of the main bottlenecks in developing mucosal vaccines is the lack of accurate animal models. In this study, a vesicular stomatitis virus (VSV)-vectored Middle East respiratory syndrome coronavirus (MERS-CoV) mucosal vaccine was designed for investigations. Compared with the VSV backbone, rVSVΔG-MERS-S exhibited altered cellular tropism, as determined by MERS-S. In wild-type (WT) C57BL-6J mice and hamsters, the nasal spray of rVSVΔG-MERS-S was poorly immunogenic. In contrast, rVSVΔG-MERS-S was highly immunogenic in transgenic mice (hDPP4 mice) and hDPP4-transduced hamsters harboring the functional MERS-CoV receptor. Compared with those of WT C57BL-6J mice, the nasal spray of rVSVΔG-MERS-S resulted in effective antigen-presenting cell (APC) priming, Tfh-GcB-plasma cell (pC) proliferation, and robust humoral and cellular responses, together with the activation of antiviral signaling pathways in hDPP4 mice. Similarly, rVSVΔG-MERS-S was highly immunogenic in alpacas and rhesus monkeys, which are naturally susceptible to MERS-CoV and harbor the effective DPP4 receptor. The alignment of hDPP4 receptors in these animals revealed that L294, I295, and R336 in DPP4 are key residues contributing to differences in sensitivity across species. Consistently, a high binding affinity was observed between human, alpacas, and rhesus monkey DPP4 receptors and MERS-CoV receptor binding domains (RBDs) compared with that of mice and hamster. Overall, this proof-of-concept study not only guides the selection of appropriate animal models for the evaluation of mucosal vaccines of MERS but also provides evidence that functional receptors DPP4 in animal models are prerequisites for the immune performance of the MERS mucosal vaccine.

Keywords: Middle East respiratory syndrome; animal model; binding affinity; dipeptidyl peptidase-4; mucosal vaccines.

 
Back
Top